INTRODUCTION
Epiretinal membrane (ERM) is a commonly encountered vitreoretinal interface anomaly with a prevalence of approximately 10% in the adult population. 1 It is usually found in conjunction with a posterior vitreous detachment (PVD) at the time of diagnosis 2 and is often treated with pars plana vitrectomy (PPV) and membrane peeling when symptomatic. PPV is generally successful at improving visual acuity (VA) and/or metamorphopsia. 3, 4 At times, however, visual recovery can be hindered by macular edema in the post-vitrectomy period. 5 Macular edema after ERM peeling may be seen for a number of reasons. Pathologic preexistent edema due to the ERM may be slow to clear, persist or even worsen following the trauma of mechanical membrane peeling. Furthermore, diffuse intrinsic thickening of the macula is often seen during the postoperative recovery period -so much so that the macula rarely regains its native foveal contour after ERM stripping. More rarely, true postsurgical inflammatory-mediated cystoid macular edema (CME) may develop and can worsen visual outcomes. [5] [6] [7] [8] No definitive guidelines exist for the management of post-membrane peeling CME. Upon diagnosis, many clinicians initially treat with topical steroids and nonsteroidal anti-inflammatory drugs (NSAIDs) and treat refractory cases with periocular or intraocular steroids. 9 Some have reported success with a more proactive treatment regimen in an effort to optimize postoperative visual outcomes, such as the injection of intravitreal steroid at the time of membrane peeling. This serves two purposes: expediting the return of normal macular morphology from the thickened con-tour, and preventing the development of postoperative CME. 5, 10, 11 Intravitreal triamcinolone acetonide (IVTA) (Triesence; Alcon, Fort Worth, TX) is a corticosteroid that is widely utilized to treat macular edema 12 and to improve intraoperative visualization as an effective surgical adjunct. 13 Visual outcomes following vitrectomy with intraoperative IVTA have had mixed results compared to outcomes in cases done without the use of IVTA. [13] [14] [15] [16] The limited effect of intraoperative IVTA may be due to its relatively fast clearance in vitrectomized eyes, which may limit its impact on macular edema. 17, 18 Thus, there may be rationale for the use of a sustained-release corticosteroid formulation at the completion of vitrectomy and membrane peeling to treat postoperative macular edema of all causes with therapeutic steroid doses for several months and, thus, more quickly and effectively improve visual outcomes.
The dexamethasone intravitreal implant (DEX) (Ozurdex; Allergan, Irvine, CA), injected intravitreally, provides a slow-release, steady dose of potent steroid. 19 We hypothesized that DEX may therefore be advantageous over IVTA as an intraoperative adjunct to reduce macular edema following vitrectomy with membrane peeling. In this study, we compared the visual and anatomic outcomes of patients with symptomatic ERMs who underwent PPV with membrane peeling and received either DEX or IVTA intraoperatively at the completion of the cases.
PATIENTS AND METHODS
This study is a retrospective, interventional, case-control study of consecutive patients treated with intraoperative IVTA or DEX at the time of vitrectomy with ERM peeling by two authors (TSH, JDW) between February 2013 and February 2015. All patients who received the DEX implant were aware of its off-label use and provided written informed consent. Exclusion criteria included concurrent fullthickness or lamellar macular holes, other macular pathology felt to potentially limit postoperative visual acuity (VA), and other vitreoretinal pathologies that required surgical intervention during the same surgery as the ERM peel. Those with follow-up of less than 3 months were excluded. Patients without sufficient follow-up imaging using spectral-domain optical coherence tomography (SD-OCT) were also excluded. There were no exclusion criteria regarding the etiology of the ERM. Institutional review board approval was granted, and the study complied with the Health Insurance Portability and Accountability Act of 1996 and conformed to the tenets of the Declaration of Helsinki.
Outcome Measures
Outcome measures included best-corrected visual acuity (BCVA), intraocular pressure (IOP), and central macular thickness (CMT) at 1, 2, 3, and 6 months postoperatively. We measured BCVA using an autorefractor-based acuity analyzer and IOP using a portable tonometer. The morphologic features of the macula were assessed by SD-OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany). CMT was measured as the thickness from the internal limiting membrane (ILM) to the retinal pigment epithelium at the fovea, as measured by the automated segmentation software and with manual segmentation (as needed) to correct for any errors.
Surgical Techniques
All surgeries were performed using 25-gauge PPV (Constellation; Alcon, Fort Worth, TX), with one exception: a single patient underwent 27-gauge vitrectomy (Constellation; Alcon) in the IVTA arm (Video available at www.Healio.com/ophthalmology/journals/osli). Valved trocar entry systems were used in all cases. After induction of a PVD (when necessary) and core vitrectomy, indocyanine green (ICG)-assisted membrane peeling was performed with removal of both the ERM and ILM using disposable endgrasping intraocular forceps. Intravitreal injection of steroids was delivered at the end of each case. For IVTA injections, either 1 mg (JDW) or 4 mg (TSH) were injected. DEX insertions were performed in the inferotemporal quadrant under direct visualization with a wide-angle viewing system. Gentle force was applied on the injector gradually to ensure that the implants were not released rapidly to cause projectile damage to the retina. Implant positioning onto the inferior vitreous base was confirmed with scleral depression. Postoperative drops were prescribed at the discretion of the surgeon but, in most patients, this included an antibiotic, a cycloplegic agent, and prednisolone acetate 1% four times a day with a standardized 1-month taper. Topical steroids were prescribed less frequently toward the end of the study period for DEX patients.
Statistical Analysis
Snellen VA was converted to logarithm of the minimum angle of resolution (logMAR) units for statistical analyses. Paired variables pre-and postoperatively were analyzed using the Wilcoxon signedrank test. Comparisons of means were performed using the Mann-Whitney U test. Nonparametric distribution was confirmed using histogram plots. All statistical tests were two-tailed and significance was defined as a P value of less than .05. Statistical analyses were performed using Stata version 9.0 (StataCorp, College Station, Texas).
RESULTS
Fifty-five eyes from 55 participants were included in the study. Table 1 outlines baseline demographic and clinical characteristics. No differences were found between the two groups prior to vitrectomy with respect to BCVA, CMT, and IOP.
Nineteen eyes were treated with intraoperative DEX and 36 eyes with IVTA. No intra-or perioperative complications were observed in either group in this series, including vitreous hemorrhage, hypotony, or infectious endophthalmitis. Table 2 outlines BCVA and CMT at 1, 2, 3, and 6 months postoperatively. Vision and CMT improved in both arms.
Visual Acuity
At the 3-month follow-up visit, both the DEX arm and the IVTA arm demonstrated a statistically significant improvement in logMAR BCVA compared to baseline (P = .016 and P < .001, respectively). No difference was noted between the two arms (P = .633) when directly compared with one another. At the 6-month follow-up visit, BCVA was improved from baseline in the DEX arm, but marginally lost statistical significance (P = .081), whereas the improvements observed in the IVTA arm remained significant (P = .001).
Central Macular Thickness
Both the DEX arm and the IVTA arm demonstrated statistically significant reductions in CMT as early as postoperative month 1 (P < .001 for both arms), and this difference remained significant through postoperative month 6. However, no significant difference was noted when comparing the DEX arm to the IVTA arm (P = .775). There were no cases of overt new postoperative CME in either group.
Intraocular Pressure
In the DEX group, three patients experienced IOP elevations of 10 mm Hg or more from baseline at 1 week and 1 month postoperatively. No IOP elevations were noted at the 2-, 3-, or 6-month follow-up visits. No new IOP-lowering medications were required in any patients at the time of latest follow-up. In the IVTA group, four patients experienced IOP elevations of 10 mm Hg or more from baseline: four patients at 1 week, of whom, one patient persisted at 1 month. Three of the four patients required temporary additional IOP-lowering medications. No new IOP-lowering medications were required at the latest follow-up in this group, either. No patients in either group experienced IOP elevations more than 20 mm Hg from baseline at any follow-up visit.
None of the participants in either the DEX or IVTA group who were phakic at baseline required cataract surgery during the 6-month follow-up period. In eyes receiving DEX, there were no cases of anterior chamber migration of the steroid pellet. One participant who received DEX developed a maculasparing retinal detachment 2 months after the initial surgery due to a small anterior break in the superior periphery, in a location presumably without contact with the DEX implant. The patient underwent a successful repair of the retinal detachment via vitrectomy, and final visual acuity was 20/50, compared to 20/80 prior to the ERM peel. No patients in the IVTA arm required any subsequent vitreoretinal surgery.
DISCUSSION
Vitrectomy with membrane peeling is an effective treatment for symptomatic ERM. 3, 4 However, visual recovery may take several months to 1 year 20, 21 as the retinal morphology slowly normalizes. OCT imaging shows that the inner, 10, 11, 22 middle, 23 and outer retina 24 become more compact after membrane peeling, and these anatomic changes correlate with visual acuity improvement. 10, 11, [22] [23] [24] Several groups have investigated the use of intravitreal triamcinolone at the end of the vitrectomy to expedite the remodeling of edematous postoperative retinal tissue. [13] [14] [15] [16] 26 Investigators posit that postoperative retinal thickening is partly due to disruption of the blood-retinal barrier and release of inflammatory cytokines from preoperative mechanical traction and then subsequent surgical manipulation. 25 ed at the end of the case. 26 At 1 week postoperatively, 84% of patients had already achieved their final visual and anatomic improvements. These findings appear to be superior to those from previous studies that examined membrane peeling without IVTA.
Follow-up studies have shown more variable results. [13] [14] [15] [16] Lai et al. reported on a retrospective casecontrol study of 98 patients that compared outcomes of ERM peels with or without the use of adjunctive IVTA (2 mg) at the end of the case. 13 In their study, eyes injected with IVTA showed no visual or anatomic benefit when compared to those not injected with IVTA. Two other case-control studies also demonstrated no significant difference in outcomes between patients treated with or without IVTA (4 mg) following ERM peels. 14, 15 However, a recent casecontrol study of 75 patients showed that the use of intraoperative IVTA (4 mg) provided greater macular thickness reduction in the IVTA arm than in the controls arm after a mean follow-up of 8 months. 16 There is no consensus in the literature as to whether IVTA is an efficacious adjunct to ERM removal surgery for several reasons. Macular thickening after ERM peeling likely results from both mechanical and inflammatory factors. Mechanically induced diffuse retinal thickening may outlast the short-term effects of IVTA on inflammatory cytokines, effects which are further shortened by the more rapid clearance of IVTA in the vitrectomized eye compared to the nonvitrectomized eye. 18, 19 A more potent, longer-lasting medication may possibly be able to circumvent these issues.
Many corticosteroids are used in medicine, but variations in their chemical structures result in differing clinical effects. Dexamethasone has 12.5 times more anti-inflammatory potency than triamcinolone. 12 It is also the most water-soluble glucocorticoid. Thus, it has the shortest half-life and is thought to be least likely to aggregate in the trabecular meshwork and thus cause intraocular pressure elevation. 27 The intraocular effects of this short-lived steroid are extended by boarding it to a sustained-release drug delivery device, such as the biodegradable copolymer matrix used in the DEX implant. We hypothesized that the DEX implant would be a useful intraoperative adjunct to ERM peeling because its greater potency and prolonged exposure time compared to IVTA may be more effective at improving outcomes in the post-vitrectomy eye. [28] [29] [30] Prior reports of the use of DEX for ERM surgery have been limited to the management of refractory postoperative CME after PPV with ERM peeling. 31, 32 In this study, we focused on the prophylactic placement of DEX to hasten and improve the therapeutic endpoint of normalized macular contour. Preliminary data from a prospective, single-armed study of 23 patients with diabetic macular edema and ERM who received DEX at the time of ERM peeling recently showed that both VA and central retinal thickness improved during the 6-month follow-up period. This series, however, had no IVTA or control arm and reported largely expected results. 33 In contrast, however, the findings from our study did not support our initial hypothesis. We found that the use of either glucocorticoid intraoperatively at the completion of ERM peeling resulted in significant improvement in VA and CMT without any significant differences in visual or anatomic outcomes between treatment arms. There was a trend towards earlier visual improvement in the DEX patients, particularly at month 2, but this did not reach statistical significance. However, the DEX arm did not demonstrate greater reductions in CMT from baseline than the IVTA group at any time point but rather, the IVTA group had more times points with significant improvements in CMT from baseline than the DEX group.
There are numerous limitations to our study. It is retrospective and therefore includes inherent selection bias, particularly in the absence of any specific predefined surgical criteria. These biases may be more prominent given the modest sample size. Fortunately, baseline preoperative characteristics between the DEX and IVTA groups were essentially identical. An additional study limitation is the absence of a control arm in which eyes received no intraoperative adjunctive steroids. This was because the authors have always used intravitreal steroids at the end of ERM peels, and eyes with no intraoperative steroid would have had to come from other surgeons. It remains possible that the visual and anatomic improvements observed were solely due to the membrane peeling, though it has become increasingly common for surgeons to use adjunctive steroids either intravitreally or otherwise during such procedures. Data from more surgeons could have been included, but intersurgeon variability in patient selection and postoperative management may have influenced an accurate interpretation of results. Finally, we did not analyze OCT findings of individual retinal layers, which may or may not have shown differences between the DEX and IVTA groups, though this was not the aim of this study. Future evaluations may address such issues.
In conclusion, our study showed that vitrectomy with membrane peeling with intraoperative injection of either DEX or IVTA at the completion of the case improved visual acuity and macular thickness. We found no significant differences in the amount or pace of visual and anatomic improvement between the two drugs. We saw no cases of new overt postoperative cystoid macular edema in either group, and both medications were safely utilized as a surgical adjunct. Our data suggest that IVTA may be the preferred choice until further studies suggest otherwise, because it produces similar results at a lower cost.
